monovalent influenza vaccine (MF-59-adjuvanted) (Avidity NanoMedicines/Transgene/University of Siena/University of Turin)

N/A

Report date: 2025/01/26 17:12:00

Base Information

Drug Namemonovalent influenza vaccine (MF-59-adjuvanted) (Avidity NanoMedicines/Transgene/University of Siena/University of Turin)
Drug Alias NameN/A
ClassificationVaccines > Application > Prophylactic vaccine
Mechanisms of ActionImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsInfluenza, Human
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesItalyFrance
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAvidity Biosciences Inc
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsInfluenza, Human
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A